PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma?

被引:0
|
作者
Ungefroren, Hendrik [1 ,2 ]
机构
[1] Univ Hosp Schleswig Holstein, Dept Med 1, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[2] Univ Lubeck, Ratzeburger Allee 160, D-23538 Lubeck, Germany
关键词
TGF-BETA; PROGRESSION; PROMOTES; CANCER;
D O I
10.1042/CS20241916
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Malignant progression of pancreatic ductal adenocarcinoma (PDAC) is driven by transforming growth factor (TGF)-(31 through extensive cross-talk with other signalling pathways. Prompted by the observation that the ubiquitous protein programmed cell death 10 (PDCD10) is more abundantly expressed in PDAC tumour tissue compared with normal pancreas and highly correlated with reduced patient survival, authors examined its function as a modulator of TGF-(3 signalling in PDAC. Cytotoxicity assays with PDAC-derived showed that PDCD10 renders cells more chemoresistant to anticancer drugs. Moreover, PDCD10 promoted TGF-(31-dependent proliferation by inactivating the retinoblastoma 1 protein (pRb) via a SMAD4-dependent pathway, and TGF-(31-driven EMT by increasing ERK1/2 activation via a non-SMAD4 pathway. Phosphoryla- tion of pRB and ERK by PDCD10 is facilitated by binding of PDCD10 to MST4. Targeting PDCD10 in PDAC patients may represent a promising new strategy to improve TGF-(3 targeted therapies
引用
收藏
页数:6
相关论文
共 50 条
  • [41] STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target
    Al-Hetty, Hussein Riyadh Abdul Kareem
    Abdulameer, Sada Jasim
    Alkubaisy, Sami Awad
    Zaid, Sawsan Ali
    Jalil, Abduladheem Turki
    Jasim, Ihsan Khudhair
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 245
  • [42] Prolactin Receptor, a Novel Target for Pancreatic Ductal Adenocarcinoma
    Dandawate, P.
    Kaushik, G.
    Subramaniam, D.
    Ghosh, C.
    Choudhury, S.
    Standing, D.
    Ramamoorthy, P.
    Manzardo, A.
    Sayed, A.
    Banerjee, T.
    Santra, S.
    Butler, M.
    Padhye, S. B.
    Baranda, J.
    Kasi, A.
    Sun, W.
    Tawfik, O.
    Coppola, D.
    Malafa, M.
    Umar, S.
    Soares, M. J.
    Saha, S.
    Weir, S. J.
    Dhar, A.
    Jensen, R. A.
    Thomas, S. M.
    Anant, S.
    PANCREAS, 2018, 47 (10) : 1382 - 1382
  • [43] PDCD10, the gene mutated in cerebral cavernous malformation 3, is expressed in the neurovascular unit
    Tanriover, Gamze
    Boylan, Arianne J.
    DiLuna, Michael L.
    Pricola, Katie L.
    Louvi, Angeliki
    Gunel, Murat
    NEUROSURGERY, 2008, 62 (04) : 930 - 938
  • [44] It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
    Knickmeier, Christin
    Noubissi Nzeteu, Gaetan Aime
    Gibbs, Bernhard F.
    Hoogwater, Frederik J. H.
    Nijkamp, Maarten W.
    Bockhorn, Maximilian
    Meyer, N. Helge
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [45] Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3
    Guclu, B
    Ozturk, AK
    Pricola, KL
    Bilguvar, K
    Shin, D
    O'Roak, BJ
    Gunel, M
    NEUROSURGERY, 2005, 57 (05) : 1008 - 1012
  • [46] PDCD10, the gene mutated in cerebral cavernous malformation 3, is expressed in the neurovascular unit - Comments
    Hodge, Charles J., Jr.
    Awad, Issam A.
    Macdonald, R. Loch
    Dunn, Ian F.
    Friedlander, Robert M.
    NEUROSURGERY, 2008, 62 (04) : 938 - 938
  • [47] Histone demethylase KDM3A: Epigenetic target for pancreatic ductal adenocarcinoma (PDAC)
    Sainathan, Satheesh K.
    Paul, Santanu
    Palaniyandi, Kanagaraj
    Subramaniam, Dharmalingam
    Ramalingam, Satish
    Tawfik, Ossama W.
    Iwakuma, Tomoo
    Welch, Danny R.
    Padhye, Subhash B.
    Anant, Shrikant
    Dhar, Animesh
    CANCER RESEARCH, 2015, 75
  • [48] IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma
    Cruz Ramos, M.
    Rodriguez-Remirez, M.
    Minguez, P.
    Cebrian, A.
    del Puerto-Nevado, L.
    Celdran, A.
    Garcia-Foncillas Lopez, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 12 - 13
  • [49] MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma
    Ding, Feng
    Zhang, Shuang
    Gao, Shaoyang
    Shang, Jian
    Li, Yanxia
    Cui, Ning
    Zhao, Qiu
    ONCOTARGET, 2017, 8 (38) : 64224 - 64236
  • [50] The trend toward more target therapy in pancreatic ductal adenocarcinoma
    Deiana, Chiara
    Agostini, Margherita
    Brandi, Giovanni
    Giovannetti, Elisa
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (07) : 525 - 565